45 CHF CHF 45.00
AG-CR1-3591-M02525 mgCHF 45.00
AG-CR1-3591-M100100 mgCHF 150.00
AG-CR1-3591-M250250 mgCHF 290.00
|Synonyms||cis-Diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II); NSC201345; NSC241240; JM-8; Paraplatin; Cbdca|
|Merck Index||14: 1822|
|Appearance||White to off-white powder.|
|Solubility||Soluble in water.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Potent platinum-based antineoplastic agent. Analog of cisplatin (Prod. No. AG-CR1-3590) with reduced nephrotoxicity and higher stability.
- Antitumor agent.
- Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death.
- Interferes with cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in turn activate apoptosis when repair is impossible.
- Apoptosis inducer.
- Enhances radiation-induced single-strand DNA breakage.
- Chk2 inhibition with carboplatin selectively kills Wwox-deficient cells
- Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function: S.J. Harland, et al.; Cancer Res. 44, 1693 (1984)
- Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer: I.E. Smith, et al.; Cancer Treat Rep. 69, 43 (1985)
- Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer: I.E. Smith & B.D. Evans; Cancer Treat Rev. 12 (Suppl. A), 73 (1985)
- Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks: L.X. Yang, et al.; Radiation Res. 143, 302 (1995)
- Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum (II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited: G. Natarajan, et al.; Biochem. Pharmacol. 58, 1625 (1999)
- Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin: O. Heudi, et al.; Biopharm. Drug Dispos. 20, 107 (1999)
- What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)
- New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA: J. Reedijk; PNAS 100, 3611 (2003)
- High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity: J.P. Thomas, et al.; Mol. Pharmacol. 70, 23 (2006)
- p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis: S. Singh, et al.; FEBS Lett. 581, 289 (2007)
- Inhibition of transcription by platinum antitumor compounds: R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009)
- Application of electric cell-substrate impedance sensing toward personalized anti-cancer therapeutic selection: A.F. Adcock, et al.; J. Analyt. Sci. Tec. 9, 17 (2018)
- Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells: M.S. Chesnokov, et al.; Cell Death Dis. 12, 704 (2021)
- Interaction of Wwox with Brca1 and associated complex proteins prevents premature resection at double-strand breaks and aberrant homologous recombination: D. Park, et al.; DNA Rep. in press (2021)